Thorne Research launches NiaCel that supports endurance, energy and healthy aging

Thorne Research today announced the launch of NiaCel™, an innovative nutritional supplement that supports endurance, energy, and healthy aging. NiaCel™ is one of the first commercially available products to feature the ingredient NIAGEN™ from ChromaDex Corp. (OTCQB: CDXC), an innovative natural products company that provides proprietary ingredients and science-based solutions to the dietary supplement, food and beverage, animal health, cosmetic, and pharmaceutical industries.

ChromaDex developed its breakthrough patent-protected ingredient NIAGEN™ as the first and only commercially available brand of nicotinamide riboside (NR). NR, the active ingredient in NiaCel™, boosts levels of NAD+ in cells and tissue. Studies have demonstrated that increasing the levels of NAD+ can support healthy aging by stimulating mitochondrial energy production, as well as by activating sirtuin function.

Paul Jacobson, the CEO of Thorne Research, stated, "We are very excited to offer NIAGEN nicotinamide riboside to our practitioner network through this new, exclusive product launch. NiaCel provides practitioners with a powerful new solution to promote healthy aging in patients. NIAGEN is one of the most innovative new ingredients developed in the past decade. We are thrilled to partner together with ChromaDex and our practitioner-customer base to enhance patient health with the introduction of NiaCel."

Frank Jaksch, ChromaDex founder and CEO, stated, "NiaCel is truly a groundbreaking product. We are pleased to have Thorne Research feature NIAGEN, our branded nicotinamide riboside, in such a prominent product launch."


ChromaDex Corp.


  1. Richard Flemming Richard Flemming Italy says:

    This obvious company press release vastly overstates the connection between this product and the Harvard study, which is apparently the one they are referring to. It is entirely misleading of the author to imply that Nicell will produce the results seen in the animal trial. Nicell was not used in the trial, the ingredient in Nicell was not used in the trial and as a NAD+ precursor one would need to take tens of bottles of this product to achieve any increase at all in cellular NAD+ levels.

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
You might also like...
Study uses Twitter data to understand stigma against people with dementia during the pandemic